PCa

Study Shows No Impact of Hormone Therapy on PET/CT with 18F-Piflufolastat in PCa Imaging

by

Emerging research suggests that hormone therapy has no significant impact upon the diagnostic efficacy of 18F-piflufolastat PET/CT for detecting recurrent or metastatic prostate cancer. For the retrospective study, recently published in The Prostate, researchers evaluated the use of 18F-piflufolastat PET/CT (Pylarify, Lantheus) in 93 patients with elevated prostate-specific antigen (PSA) levels and suspected local recurrence … Read more

Emerging Concepts and Recommendations for MRI in Prostate Cancer Screening

by

Should men with indeterminate magnetic resonance imaging (MRI) results refrain from getting a subsequent biopsy for prostate cancer (PCa)? Is staged MRI interpretation a viable option in PCa screening? Should MRI be a first-line option in the screening of patients for PCa? In a new review, recently published in the American Journal of Roentgenology, researchers … Read more